ArticleCurrent issues in molecular biology2026
Multiscale Interactome-Guided Prioritization of Candidate Herbs and Active Compounds for Hepatic Cirrhosis Using a Biased Random Walk Algorithm.
Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hepatic cirrhosis is a progressive chronic liver disease driven by sustained inflammation, cell death, and tissue remodeling, and effective disease-modifying options remain limited. Here, we applied a multiscale interactome framework to prioritize candidate herbs and active compounds for hepatic cirrhosis. Herb-compound associations were collected from the OASIS database and mapped to experimentally supported compound-target interactions (DrugBank/TTD/STITCH), while cirrhosis-related proteins were curated from DisGeNET. Using a biased random-walk algorithm, we generated disease and herb/compound diffusion profiles on the multiscale network and ranked candidates by profile similarity and target overlap. Among the top-ranked herbs, Magnoliae Cortex, Notoginseng Radix et Rhizoma, Polygoni Cuspidati Rhizoma et Radix, and Capsici Fructus were supported by prior literature, whereas several high-ranking herbs lacked curated evidence and were highlighted as underexplored candidates, including Saposhnikoviae Radix and Fritillariae Cirrhosae Bulbus. Enrichment analyses indicated convergence on inflammatory and innate-immune pathways (TNF, Toll-like receptor, NF-κB) and apoptosis-related processes, with additional signals involving HIF-1 and PI3K-Akt pathways. Disease-focused subnetworks suggested mechanistic hypotheses for evidence-lacking compounds, including bergapten, oleic acid, and octadecanoic acid. Overall, we systematically prioritize herbal candidates and provides a mechanistic basis for follow-up validation in hepatic cirrhosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.